Table 1. Efficacy of PD-1 inhibitors for... | American Society of Hematology

Table 1.

Efficacy of PD-1 inhibitors for untreated advanced-stage classic Hodgkin lymphoma

Author, year	Study design	Number of patients	Key efficacy results
Ramchandren et al 2019⁶	Sequential nivolumab × 4, Nivolumab+AVD × 12	51	21-month PFS 83%⁸
Allen et al 2021⁷ Allen et al 2021⁹	Sequential Pembrolizumab+AVD	30	33-month PFS 100%⁹
Lynch et al 2023¹⁰ Lynch et al 2023¹¹	Pembrolizumab+AVD × 2-6	50	2-year PFS 97%¹¹
Herrera et al 2023¹²	Nivolumab+AVD vs BV+AVD	994	12-month PFS 94%¹²

Author, year	Study design	Number of patients	Key efficacy results
Ramchandren et al 2019⁶	Sequential nivolumab × 4, Nivolumab+AVD × 12	51	21-month PFS 83%⁸
Allen et al 2021⁷ Allen et al 2021⁹	Sequential Pembrolizumab+AVD	30	33-month PFS 100%⁹
Lynch et al 2023¹⁰ Lynch et al 2023¹¹	Pembrolizumab+AVD × 2-6	50	2-year PFS 97%¹¹
Herrera et al 2023¹²	Nivolumab+AVD vs BV+AVD	994	12-month PFS 94%¹²

AVD, adriamycin, vinblastine, dacarbazine; BV+AVD, brentuximab vedotin, adriamycin, vinblastine, dacarbazine; PFS, progression-free survival.